Machine-learning proteomics prioritizes four plasma markers associated with ankylosing-spondylitis activity
A plasma-proteomics study of 48 active ankylosing-spondylitis (AS) patients, 21 stable-stage patients and 35 healthy controls combined random-forest and OPLS-DA scores to prioritize candidate markers. SAA1, FERMT3, ILK and TLN1 were elevated in active-stage AS and returned toward control levels in stable-stage patients; ELISA in a separate cohort (27 active, 28 stable, 24 controls) reproduced these patterns. A combined ELISA model distinguished active AS from healthy controls with AUC 0.932. FERMT3, ILK and TLN1 are integrin-pathway proteins.
Technology: Machine-learning biomarker scoring matrix combining random forest and OPLS-DA
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: SAA1, FERMT3, ILK and TLN1 were elevated in active-stage AS and returned toward control levels in stable-stage patients; ELISA in a separate cohort (27 active, 28 stable, 24 controls) reproduced these patterns.
- Still unknown: This is an observational, cross-sectional plasma-biomarker study; it does not establish causal integrin-pathway activity, prognosis over time, treatment response, or clinical utility. The independent ELISA cohort had 79 participants and was drawn from the same clinical setting. The combined AUC 0.932 applies to active AS versus healthy controls; discrimination against other inflammatory diseases was not demonstrated. SAA1 has been previously reported as an AS-associated marker; the AI-supported novelty is the combined panel and the integrin-related proteins, not discovery of SAA1 itself.
- AI role: Random-forest classification accuracy/Gini importance and OPLS-DA variable-importance scores were combined with proteomic fold-change and significance terms to rank candidate proteins. The team then measured the four prioritized proteins by ELISA in an independent cohort.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40436140/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 85 of works of the same type, year and subfield (OpenAlex work metrics, 4 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.